Alan Melcher

30PUBLICATIONS
227CO-AUTHORS
Biologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Oct 15, 2026
Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapy.

|Oct 12, 2026
Addition of chemotherapy to radiotherapy promotes progenitor-exhausted CD8⁺ T-cell clonal dominance in head and neck cancer.

|Sep 21, 2026
Immunodominant Antiviral T Cell Responses Outcompete Antitumor T Cell Responses to Reduce the Efficacy of Oncolytic Viroimmunotherapy.

|Aug 26, 2026
Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome.

|Jun 05, 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

|Mar 06, 2026
Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy.

Winnie Fernando, Jarama Clucas, Alberto Rizzo

Pageof 5

Frequent Collaborators

17 joint publications

Kevin J Harrington

12 joint publications

Emmanuel Patin

9 joint publications

Charleen Ml Chan Wah Hak

8 joint publications

Shane Foo